Page 4 - Sanofi

Sanofi to pay Regeneron $462 million in revised immuno-oncology deal

Sanofi will pay Regeneron $462 million representing the balance of payments due under their original deal

Sanofi India: High-margin diabetic products and exports to drive profits

The top seven brands have together grown at 21 per cent annually and now account for 46 per cent of Sanofi's sales

Growth recovery on the cards for Sanofi

The year 2016 may have not been good for Sanofi India, andMarch 2017 quarter numbers did not impress either. But, the company's fortunesare seen changing for the better.The company follows a January-December financial year. While2016 performance was impacted because of the new drug pricing policy anddemonetisation, the March 2017 quarter numbers were weighed down by prolongedeffect of the note ban and lower exports revenue. Sanofi said lower exportvolumes and rupee appreciation versus the euro had an adverse impact on itssales and profitability for the quarter.These events have weighed on the stock, which at ~4,210 isnot much higher than its 52-week lows of ~4,005. However, with analystsconfident of a rebound in company performance, the correction offers a goodopportunity to buy the stock. Sanofi is well known for its brands such as Combiflam,Lantus, Avil, etc, besides its vaccines and diabetes portfolio. For itsflagship brands, the month of March itself has instigated confidence. Of

For Sanofi, better days loom ahead

The year 2016 was challenging for Sanofi India, the drug maker known for its brands such as Combiflam, vaccines and diabetes portfolio. While the drug price control impacted the company's performance in the early part of CY2016 (follows January-December accounting year), note ban weight on its December quarter numbers. These have led to its stock price remaining under pressure. But, as the impact fades out, analysts expect the company to report a strong rebound in revenue, profitability and thereby stock price, which is why they are now bullish on Sanofi. Post the company reported its December quarter and financial year performance on Monday, analysts have strong buy recommendation on the stock. The expectations stem from the fact that despite pressure due to price control, volume growth in key brands is expected to be strong and will drive overall revenue. Also, launch of new product line extensions and exports of insulin pens will mean further gains. Analysts such as Ranjit Kapadia .

Sanofi sues Glenmark, Torrent over sclerosis drug

Sanofi had received letters from Torrent and Glenmark, with a notice of their new drug applications

Sanofi Q2 net up 33% at Rs 85 crore

Total income rises to Rs 608 cr

New Sanofi vaccine facility starts commercial production

Unit will initially produce pentavalent and cholera vaccines, will be also registered for hepatitis B and tetanus shots

Sanofi scrip falls marginally a day after Combiflam recall

The Drugs Controller General of India found Sanofi's popular painkiller drug to be of sub-standard quality twice in the past three months

Sanofi recalls batches of Combiflam after regulator alert

DCGI had issued an alert twice, saying drug was sub-standard, as its disintegration in the blood stream was delayed